Clinicopathologic features and treatment advances in cancers with HER2 alterations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Human Epidermal growth factor Receptor 2 (HER2) is a critical member of the epidermal growth factor receptor (EGFR) family.
• HER2 alterations, including amplification, overexpression, and mutation, are significant in various cancers.
• HER2 serves as a vital biomarker for prognosis, predicting treatment response, and as a therapeutic target.

Purpose of the Study:

• To detail the landscape of HER2 amplification/overexpression and mutations across four major cancer types.
• To provide an updated analysis of current clinical trials targeting HER2 alterations.
• To explore the differential responses to HER2-targeting therapies and immune checkpoint inhibitors based on HER2 status.

Main Methods:

• Comprehensive review of HER2 alterations (amplification, overexpression, mutation) in breast, gastric, lung, and colorectal cancers.
• Analysis of existing clinical trial data for HER2-targeted therapies and immune checkpoint inhibitors.
• Comparative assessment of clinicopathologic features and treatment strategies for different HER2 alteration types.

Main Results:

• HER2-altered cancers exhibit diverse responses to HER2-targeting therapies and varying survival outcomes.
• HER2 amplification/overexpression and HER2 mutations present distinct clinicopathologic features and necessitate different treatment strategies within the same cancer type.
• Immune checkpoint inhibitors show varied efficacy in HER2-altered breast, gastric, and lung cancers.

Conclusions:

• The specific type of HER2 alteration significantly influences treatment efficacy and patient outcomes.
• Tailored therapeutic strategies are crucial for managing HER2-altered cancers.
• Further research into the differential effects of therapies, including immune checkpoint inhibitors, in HER2-altered cancers is warranted.